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analysis results were consistent with the base-case findings. ConClusions: Based 
on the willingness-to-pay threshold for end-of-life cancer drugs, ceritinib may be 
considered as a cost-effective option compared with other alternatives in patients 
who have progressed or are intolerant to crizotinib.
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objeCtives: This study aims to assess the cost-effectiveness of aspirin in the pri-
mary prevention of cardiovascular events (myocardial infarction (MI) and ischemic 
stroke (IS)) and colorectal cancer (CRC) in the low-risk general population in the 
United States (US). Methods: We developed and validated a Markov model to 
predict the number of primary events (MI, IS, or CRC) in US Caucasian males 
using established age-dependent risk data from the literature. Simulations were 
performed from the US healthcare system perspective using a starting cohort of 
non-smoking, non-diabetic Caucasian males aged 40 years old with low cardiovas-
cular risk (10-year risk < 5%) and normal CRC risks for the aspirin and no-aspirin 
arms. Annual cycles were simulated until 100 years old. Cost per quality-adjusted 
life year (QALY) and cost per life year (LY) were used as the primary outcome 
measures and clinical measures, numbers needed to treat (NNT) and numbers 
needed to harm (NNH), as secondary outcome measures. A 3% discount rate was 
applied to both costs and outcomes. Both deterministic and probabilistic sen-
sitivity analyses (PSA) were performed. Results: Aspirin was found to be the 
dominant strategy in the base-case analyses. NNT and NNH were 11.1 and 13.6 
respectively. One-way sensitivity analyses showed that the findings were highly 
sensitive to rates of hemorrhagic stroke, utilities of taking pill, aspirin’s effects 
on cardiovascular events, out-of-hospital MI fatality rates, and CRC risks. PSA 
showed that when willingness-to-pay (WTP) levels were varied from USD0 to 
USD100,000 per QALY gained, aspirin is likely to be cost-effective more than 80% 
of the time. ConClusions: Aspirin is likely to be cost-effective as a primary 
preventive agent. However, the finely balanced NNT and NNH made it premature 
to recommend aspirin for primary prevention of cardiovascular and CRC events 
in low-risk Caucasian males. Resources should be channeled towards conducting 
further studies to generate more precise model inputs.
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objeCtives: To evaluate the cost-effectiveness of several sequential treatment 
strategies for chronic myeloid leukemia (CML) dependent on early molecular 
response (EMR) in the Austrian healthcare context. Methods: We adapted a pre-
viously developed Markov state-transition model to incorporate different treatment 
options (imatinib, dasatinib, nilotinib) dependent on achievement of EMR after 3 
months. We analyzed eight sequential treatment strategies using cohort simula-
tion over a lifelong time horizon. Model parameters were extracted from published 
literature, epidemiological and economic databases. We applied a 3% discount for 
health outcomes and costs. We analyzed 3 different base-case scenarios for patients 
not achieving an EMR after 3-months of imatinib treatment that were switched to a 
second-generation TKI, assuming three different effectiveness for these second-gen-
eration TKIs. Comprehensive sensitivity analyses were conducted. Results: The 
base-case analysis resulted in two non-dominated strategies: (1) imatinib, followed 
by nilotinib in case of non-achieved EMR at 3 months and dasatinib after treatment 
failure or imatinib continuation in case of achieved 3-month EMR and nilotinib 
after treatment failure; (2) nilotinib followed by its continuation in case of non-
achieved EMR at 3 months or switch to imatinib in case of achieved 3 month EMR 
and dasatinib after treatment failure. Depending on the scenario, strategy 2 resulted 
in an incremental cost-effectiveness ratio (ICER) of € 84,200/QALY, € 118,500/QALY 
or € 142,200/QALY gained compared to the baseline strategy. Remaining strategies 
were excluded due to dominance. Sensitivity analyses on generic pricing of imatinib 
showed that starting with a more potent second-generation TKI and switching to 
imatinib after an achieved EMR are the preferred strategies. ConClusions: Based 
on our analyses, we suggest nilotinib and its continuation for non-achieved EMR 
at 3 months or switch to imatinib after achieved 3-month EMR and dasatinib after 
treatment failure as a cost-effective strategy for Austria if the willingness-to pay 
threshold is at least around € 120,000/QALY.
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objeCtives: The nonavalent vaccine, by protecting against five additional onco-
genic HPV types, and nine HPV types in total (6, 11, 16, 18, 31, 33, 45, 52 and 58), is 
objeCtives: This study assessed, from a societal perspective, the cost-effective-
ness of idelalisib in combination with rituximab versus rituximab monotherapy 
for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). CLL 
is the most common leukemia in the Western world and is clinically character-
ized by peripheral blood B-cell lymphocytosis as well as lymphadenopathy, orga-
nomegaly, cytopenias and systemic symptoms in advanced stages. Methods: The 
cost-effectiveness model adopted a lifetime horizon with three health states: 1) 
pre-progression; 2) post-progression and 3) death. Patients enter in the model in 
the pre-progression state and in each cycle (1 week length) may survive without 
progression; advance to post-progression or die. Remission was not considered 
in the model: patients in post-progression state remain there until death. Costs 
and benefits were estimated for the Portuguese setting, and discounted at 5%, 
as recommended by national guidelines. Univariate and probabilistic sensitivity 
analyses assessed the robustness of results. Clinical efficacy, safety and utility data 
were based on published evidence, while survival curves were extrapolated using a 
Weibull function. Costs estimation was based on Diagnosis Related Group database, 
national legislation and opinions of an experts’ panel. Model outputs included life 
years gained, quality-adjusted life years (QALYs), and incremental cost-effectiveness 
ratios (ICERs). Results: Survival gains as well as direct medical costs were higher 
with idelalisib in association with rituximab compared to rituximab monotherapy, 
but costs related to adverse events and end-of-life care were lower. The ICER was 
of 32.702€ /QALY and 15.935€ /LY. Results were sensitive to the discount rates with 
an undiscounted ICER of 21.942 € . For other parameters univariate analyses ranged 
between 31.228€ /QALY and 34.176 € /QALY. PSA resulted in a median willingness to 
pay of 34.801€ /QALYs or 17.000€ /LY. ConClusions: Idelalisib plus rituximab in 
the treatment of relapsed/refractory CLL, compared with rituximab plus placebo, 
is cost-effective in Portugal.
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objeCtives: HPV vaccination is recommended in France for girls aged 11 to 14 with 
a catch-up from 15 to 19 years old. Though, with a cumulative coverage rate (VCR) of 
less than 20% in girls aged 16 years old for the HPV vaccine, France has one of the 
lowest VCR in Europe. The objective of the present study is to estimate the burden 
that would be averted by reaching in France the VCR currently observed in several 
EU countries. Methods: A dynamic transmission model including a wide range 
of health and cost outcomes related to cervical, anal, vulvar, vaginal diseases and 
genital warts, was adapted to French setting. The health outcomes resulting from 
the vaccination of girls with quadrivalent HPV vaccine was assessed according to 
two different vaccine coverage rates: (i) the 2014 cumulative coverage rate in girls 
aged 16 years old of 17.2% (reported by the InVS in July 2014) (ii) a VCR of 70% as 
observed in several European countries. Results: The analyses demonstrated that 
reaching in France a VCR comparable to those observed in other European countries 
would lead to avert additional 3,873,070 genital warts, 582,339 CIN2/3, 78,899 cervical 
cancers, 1,253 vaginal cancers, 1,756 vulvar cancers, and 17,993 anal cancers (includ-
ing 4,774 in males) over 100 years. Overall, 27,222 deaths from HPV cancers could 
be averted by increasing the VCR at 70%. ConClusions: The present study shows 
that the suboptimal HPV vaccination coverage rate observed in France is linked 
with a tremendous loss of opportunity for the French population. Even though the 
applied VCR is not representative of the VCR of the entire targeted population, it 
is clear that benefits of HPV vaccination are still undermined. In a context where 
cancer is a health priority in France, combined efforts to improve HPV vaccination 
coverage rate must be pursued.
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objeCtives: To assess the cost-effectiveness of ceritinib versus alternatives in 
patients who discontinue treatment with crizotinib in anaplastic lymphoma kinase-
positive (ALK+) non-small cell lung cancer (NSCLC) from a Canadian healthcare 
perspective. Methods: A partitioned survival model with three health states (pro-
gression-free, progressive, and death) was developed to compare ceritinib versus 
other alternatives in patients with ALK+ NSCLC who were previously treated with 
an ALK inhibitor. Comparators were chosen based on reported utilization from a 
retrospective Canadian chart study; comparators were pemetrexed, best-support-
ive care (BSC) and historical control. Progression-free survival and overall survival 
for ceritinib were estimated using data from reported single-arm clinical trials 
(ASCEND-1(NCT01283516) and ASCEND-2(NCT01685060)). Survival data for compara-
tors were obtained from published clinical trials in general NSCLC population and 
from a Canadian retrospective chart study in ALK+ patients treated with crizotinib. 
Parametric models were used to extrapolate outcomes beyond trial period. Drug 
acquisition, administration, resource use and adverse event (AE) costs were obtained 
from public databases. Utilities for health states and disutilities for AEs based on 
EQ-5D were derived from literature. Incremental costs per quality-adjusted life year 
(QALY) gained were estimated. Univariate and probabilistic sensitivity analyses were 
performed. Results: Over 4 years, ceritinib was associated with 0.86 QALYs and 
total direct costs of $89,740 for post-ALK population. The incremental cost per QALY 
was $149,117 comparing ceritinib vs. BSC, $80,100 vs. pemetrexed, and 104,436 vs. 
historical controls. Additional scenarios included comparison to docetaxel with an 
ICER/QALY of $149,780 and utility scores reported from PROFILE 1007, with a reported 
ICER/QALY ranging from $62,543 vs. pemetrexed to $119,735 vs. BSC. Sensitivity 
